Chemical Genomics-Based Antifungal Drug Discovery: Targeting Glycosylphosphatidylinositol (GPI) Precursor Biosynthesis
Paul A. Mann(Merck & Co., Inc., Rahway, NJ, USA (United States)), Terry Roemer(Merck Canada Inc. (Canada)), Sandra Koseoglu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jennifer Nielsen Kahn(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xinwei Sher(Merck & Co., Inc., Rahway, NJ, USA (United States)), Olga Genilloud(Fundación Medina), Charlie Boone(University of Toronto), Kristine Devito(Merck & Co., Inc., Rahway, NJ, USA (United States)), Qian Si(Merck & Co., Inc., Rahway, NJ, USA (United States)), Amy Flattery(Merck & Co., Inc., Rahway, NJ, USA (United States)), Guy H. Harris(Merck & Co., Inc., Rahway, NJ, USA (United States)), Elena Kuzmin(University of Toronto), Michael Costanzo(University of Toronto), Charles G. Garlisi(Merck & Co., Inc., Rahway, NJ, USA (United States)), Bo Jiang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hao Wang(Beijing Institute of Genomics), Nuria de Pedro(Fundación Medina), Catherine A. McLellan(Howard Hughes Medical Institute), Susan Lindquist(Howard Hughes Medical Institute), Nicholas Murgolo(Merck & Co., Inc., Rahway, NJ, USA (United States))
DSpace@MIT (Massachusetts Institute of Technology)
December 1, 2014
Cited by 0
Related Papers
New developments in RiPP discovery, enzymology and engineering
|Natural Product Reports|2020|793